PD-1 and BTLA and CD8⁺ T-cell “exhaustion” in cancer

References

• Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77:4911 - 27; http://dx.doi.org/10.1128/JVI.77.8.4911-4927.2003; PMID: 12663797
   PubMed Web of Science ®Google Scholar
• Youngblood B, Wherry EJ, Ahmed R. Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells. Curr Opin HIV AIDS 2012; 7:50 - 7; http://dx.doi.org/10.1097/COH.0b013e32834ddcf2; PMID: 22134341
   PubMedGoogle Scholar
• Angelosanto JM, Wherry EJ. Transcription factor regulation of CD8+ T-cell memory and exhaustion. Immunol Rev 2010; 236:167 - 75; http://dx.doi.org/10.1111/j.1600-065X.2010.00927.x; PMID: 20636816
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114:1537 - 44; http://dx.doi.org/10.1182/blood-2008-12-195792; PMID: 19423728
   PubMed Web of Science ®Google Scholar
• Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest 2011; 121:2350 - 60; http://dx.doi.org/10.1172/JCI46102; PMID: 21555851
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682 - 7; http://dx.doi.org/10.1038/nature04444; PMID: 16382236
   PubMed Web of Science ®Google Scholar
• Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 2009; 83:9122 - 30; http://dx.doi.org/10.1128/JVI.00639-09; PMID: 19587053
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207 - 12; http://dx.doi.org/10.1016/j.coi.2011.12.009; PMID: 22236695
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Ibegbu CC, Masopust D, Miller JD, Araki K, Doho GH, et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol 2011; 186:4200 - 12; http://dx.doi.org/10.4049/jimmunol.1001783; PMID: 21383243
   PubMed Web of Science ®Google Scholar
• Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010; 120:157 - 67; http://dx.doi.org/10.1172/JCI40070; PMID: 20038811
   PubMed Web of Science ®Google Scholar
• Youngblood B, Oestreich KJ, Ha SJ, Duraiswamy J, Akondy RS, West EE, et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 2011; 35:400 - 12; http://dx.doi.org/10.1016/j.immuni.2011.06.015; PMID: 21943489
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850 - 4; http://dx.doi.org/10.1126/science.1076514; PMID: 12242449
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116; PMID: 21498393
   PubMed Web of Science ®Google Scholar
• Wu RFM-A, Forget M-A, Chacon J, Bernatchez C, Haymaker C, Chen JQ, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012; 18:160 - 75; http://dx.doi.org/10.1097/PPO.0b013e31824d4465; PMID: 22453018
   PubMed Web of Science ®Google Scholar
• Schwartz RH. T cell anergy. Annu Rev Immunol 2003; 21:305 - 34; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141110; PMID: 12471050
   PubMed Web of Science ®Google Scholar
• Krönig H, Julia Falchner K, Odendahl M, Brackertz B, Conrad H, Muck D, et al. PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease. Int J Cancer 2012; 130:2327 - 36; http://dx.doi.org/10.1002/ijc.26272; PMID: 21717461
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37.
   Google Scholar
• Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012; 72:887 - 96; http://dx.doi.org/10.1158/0008-5472.CAN-11-2637; PMID: 22205715
   PubMed Web of Science ®Google Scholar
• Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012; 7:e30852; http://dx.doi.org/10.1371/journal.pone.0030852; PMID: 22347406
   PubMed Web of Science ®Google Scholar
• Sakthivel P, Gereke M, Bruder D. Therapeutic intervention in cancer and chronic viral infections: antibody mediated manipulation of PD-1/PD-L1 interaction. Rev Recent Clin Trials 2012; 7:10 - 23; http://dx.doi.org/10.2174/157488712799363262; PMID: 22023178
   PubMedGoogle Scholar